Pfizer To Acquire Ferrosan's Consumer Healthcare Business

PfizerPfizer Inc. (NYSE:PFE) has entered into a definitive agreement to purchase Ferrosan's consumer healthcare business, which includes dietary supplements and lifestyle products, from Altor 2003 Fund GP Limited.

Based in Copenhagen, Ferrosan is an innovative and long-established consumer healthcare company in the Nordic region with a portfolio of leading brands. Since 1920, Ferrosan has grown to serve a broader market including Russia, the Ukraine, Poland, Turkey and many countries throughout Central and Eastern Europe.

"Ferrosan is an excellent strategic fit that strengthens our presence in dietary supplements with a new set of compelling brands and product pipeline," said Paul Sturman, president, Pfizer Consumer Healthcare. "The transaction will mark an important step towards expanding Ferrosan's brands through Pfizer's global footprint. As an immediate result of this acquisition, we will gain greater distribution and scale for Pfizer’s well-known brands such as Centrum® and Caltrate® in Ferrosan's regions."

Ferrosan's portfolio of products include Multi-tabs®, a popular multivitamin brand, Bifiform®, a leading probiotic, Fri Flyt/Active Omega, an Omega 3 product, and IMEDEEN® premium oral skincare brands. These Ferrosan brands are among the top-selling products in their respective categories.

Ola Erici, President of Ferrosan, said, "We are very pleased that Ferrosan's innovative portfolio of leading brands will be joining Pfizer. We expect that, as part of the Pfizer portfolio, our products will build on their industry-leading positions and become available in more countries around the world. And, at the same time, Pfizer will be able to leverage its footprint in key Ferrosan markets with new Pfizer products."

The transaction, which is subject to customary closing conditions, including regulatory approval in certain jurisdictions, is expected to close during the second quarter 2011. Financial terms were not disclosed.

Pfizer's financial advisors were Barclays Capital and Guggenheim Securities, LLC. Skadden, Arps, Slate, Meagher & Flom LLP acted as U.S. counsel for Pfizer with Gorrissen Federspiel advising Pfizer on Danish law.

Pfizer Inc.: Working together for a healthier world™
At Pfizer, we apply science and our global resources to improve health and well-being at every stage of life. We strive to set the standard for quality, safety and value in the discovery, development and manufacturing of medicines for people and animals. Our diversified global health care portfolio includes human and animal biologic and small molecule medicines and vaccines, as well as nutritional products and many of the world's best- known consumer products. Every day, Pfizer colleagues work across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases of our time. Consistent with our responsibility as the world’s leading biopharmaceutical company, we also collaborate with health care providers, governments and local communities to support and expand access to reliable, affordable health care around the world. For more than 150 years, Pfizer has worked to make a difference for all who rely on us.

About Ferrosan Consumer Health
Ferrosan was founded in 1920 and has a long-standing pharmaceutical heritage. Headquartered in Copenhagen, Ferrosan Consumer Health today employs approximately 640 people and is engaged in the sale of science-based consumer healthcare products primarily in the Nordic region and the emerging markets of Russia and Central and Eastern Europe. Ferrosan Consumer Health offers a focused product portfolio of well-established brands including Multi-tabs®, the reference product in the multivitamin segment in the Nordic region, Bifiform®, a market-leading fast growing probiotics product range, Fri Flyt/Active Omega-3, a premium product range addressing the omega-3 market for heart and joint health, and IMEDEEN®, the global leader within oral skin care.

About Altor
The Altor funds (Altor) are private equity funds comprising the "Altor 2003 Fund", with committed capital of EUR 650 million, the "Altor Fund II", with committed capital of EUR 1,150 million and also the "Altor Fund III", with committed capital of EUR 2,000 million. Altor is advised by Altor Equity Partners. Altor invests in companies in the Nordic region with a focus on value creation through growth initiatives, strategic development and operational improvements and has since its inception in 2003 invested in 27 platform investments and more than 30 add-on acquisitions.

Most Popular Now

FDA approves drug to treat ALS

The U.S. Food and Drug Administration today approved Radicava (edaravone) to treat patients with amyotrophic lateral sclerosis (ALS), commonly referred to as Lou Gehrig's...

Read more

FDA approves first cancer treatment for any solid …

The U.S. Food and Drug Administration today granted accelerated approval to a treatment for patients whose cancers have a specific genetic feature (biomarker). This is th...

Read more

Sanofi and Regeneron announce FDA Approval of Kevz…

Sanofi and Regeneron Pharmaceuticals, Inc. have announced the U.S. Food and Drug Administration (FDA) approval of Kevzara® (sarilumab) for the treatment of adult patients...

Read more

AstraZeneca marks a key milestone with the ‘toppin…

AstraZeneca marks a key milestone in its successful move to Cambridge, UK, with the 'topping out' of its new, state-of-the-art, strategic R&D centre and global corporate ...

Read more

FDA approves first treatment for a form of Batten …

The U.S. Food and Drug Administration today approved Brineura (cerliponase alfa) as a treatment for a specific form of Batten disease. Brineura is the first FDA-approved ...

Read more

Abbott announces CE Mark and first use of the worl…

Abbott (NYSE: ABT) today announced CE Mark and first use of the new Confirm RxTM Insertable Cardiac Monitor (ICM), the world's first smartphone compatible ICM that will h...

Read more

Imfinzi significantly reduces the risk of disease …

AstraZeneca and MedImmune, its global biologics research and development arm, today announced positive results for the Phase III PACIFIC trial, a randomised, double-blind...

Read more

Antibiotic doxycycline may offer hope for treatmen…

A study published in the journal Scientific Reports suggests that doxycycline, an antibiotic used for over half a century against bacterial infections, can be prescribed ...

Read more

Novartis exercises exclusive option agreement with…

Novartis announced today that it has notified Conatus Pharmaceuticals Inc., of its exercise of the option to an exclusive license for the global development and commercia...

Read more

England's Cancer Drugs Fund 'failed to deliver mea…

Analysis of the drugs that were approved for use by the NHS Cancer Drugs Fund (CDF) in England has shown that the fund was not good value for patients and society and may...

Read more

High levels of exercise linked to nine years of le…

Despite their best efforts, no scientist has ever come close to stopping humans from aging. Even anti-aging creams can't stop Old Father Time. But new research from Brigh...

Read more

Vitamin A deficiency is detrimental to blood stem …

Many specialized cells, such as in the skin, gut or blood, have a lifespan of only a few days. Therefore, steady replenishment of these cells is indispensable. They arise...

Read more

Pharmaceutical Companies

[ A | B | C | D | E | F | G | H | I | J | K | L | M | N | O | P | Q | R | S | T | U | V | W | X | Z ]